Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

Drug Metabolism and Disposition

Volumn 38, Issue 6, 2010, Pages 981-987

  Foti, Robert S ^a   Rock, Dan A ^a   Wienkers, Larry C ^a   Wahlstrom, Jan L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 2 METHYLPROPYL) [5 (7 METHOXYQUINOLIN 4 YLOXY)PYRIDIN 2 YL] 5 METHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOLE 4 CARBOXAMIDE; AMG 458; AMIDE; BUDESONIDE; BUSPIRONE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; FELODIPINE; FLUOXETINE; FLUTICASONE; FLUVOXAMINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NIFEDIPINE; QUINIDINE; SERTRALINE; SILDENAFIL; SIMVASTATIN; TERFENADINE; TESTOSTERONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; AREA UNDER CURVE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FELODIPINE; MICROSOMES, LIVER; MIDAZOLAM; MOLECULAR STRUCTURE; NIFEDIPINE; QUINIDINE; SUBSTRATE SPECIFICITY; TESTOSTERONE;

EID: 77952302682     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032094     Document Type: Article

References (25)

1. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
2. Davidson MH (2002) Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf 1:207-212.
3. Foti RS and Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523-528.
4. Frassetto LA, Poon S, Tsourounis C, Valera C, and Benet LZ (2007) Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81:828-832. (Pubitemid 46788293)
5. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
6. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190. (Pubitemid 41058254)
7. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304. (Pubitemid 46174829)
8. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844. (Pubitemid 40686638)
9. Jalava KM, Olkkola KT, and Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61:410-415. (Pubitemid 27195943)
10. Jorga A, Holt DW, and Johnston A (2004) Therapeutic drug monitoring of cyclosporine. Transplant Proc 36:396S-403S.
11. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
12. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
13. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, et al. (2008) Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7- methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2, 3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem 51:3688-3691.
14. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
15. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
16. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3a4 and CYP3a5. Drug Metab Dispos 31:938-944.
17. Po AL and Zhang WY (1998) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351:1829-1830.
18. Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, and Levy RH (2007) Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab 8:810-814. (Pubitemid 350238910)
19. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
20. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
21. Tracy TS (2003) Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 4:341-346.
22. Wahlstrom JL, Rock DA, Slatter GS, and Wienkers LC (2006) Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opin Drug Discov 1:677-691.
23. White CM, Ferraro-Borgida MJ, Moyna NM, McGill CC, Ahlberg AW, Thompson PD, Chow MS, and Heller GV (1998) The pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease. J Clin Pharmacol 38:792-797. (Pubitemid 28450401)
24. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
25. Zürcher RM, Frey BM, and Frey FJ (1989) Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 45:366-372.